Back to results
US 2026/0306582 A1Published application
Psma specific binding proteins for cancer diagnosis and treatment
AssigneeNavigo Proteins GmbH
InventorsEva Bosse-Doenecke, Manja Gloser-Bräunig, Florian Settele, Erik Fiedler, Ulrich Haupts
Life of this patent
Estimating the term…
Abstract
The present invention relates to new binding proteins that are specific for prostate specific membrane antigen (PSMA). The invention further refers to PSMA binding proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PSMA binding proteins in medicine, for example, in diagnosis and therapy of cancer associated with PSMA expression.
Claims20
A prostate specific membrane antigen (PSMA) binding protein, comprising one or more ubiquitin muteins based on SEQ ID NO:
- 1 and having an amino acid sequence identity of at least 92% to SEQ ID NO:
- 25 or SEQ ID NO:
- 35, wherein the PSMA binding protein has a specific binding affinity to the extracellular domain of PSMA of less than 100 nM.
Dependencies are inferred from the claim text.